Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 6/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 6/20 | 1.00 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | TNKS | O95271 | 1/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.55 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.55 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.55 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.55 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.55 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.55 |
| ▸ | AHR | P35869 | 2/20 | 0.50 |
| ▸ | S100A4 | P26447 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dibenzofuran SCHEMBL28066911 | 1.00 | MEN1 (1.00) | MEN1KMT2AMAPTTNKSPARP1 | |
| SCHEMBL9186989 | 0.92 | MEN1 (0.84) | MEN1KMT2AMAPTTNKSPARP1 | |
| SCHEMBL7703302 | 0.91 | MEN1 (0.82) | MEN1KMT2AMAPTS100A4ALDH1A1 | |
| SCHEMBL10810205 | 0.90 | MEN1 (0.82) | MEN1KMT2AMAPTTNKSPARP1 | |
| SCHEMBL2340821 | 0.89 | MAPT (0.81) | MEN1KMT2AMAPTTNKSPARP1 | |
| Dibenzofuran SCHEMBL27495466 | 0.89 | MEN1 (0.79) | MEN1KMT2AMAPTTNKSPARP1 | |
| SCHEMBL2990038 | 0.85 | MAPT (0.73) | MEN1KMT2AMAPTTNKSPARP1 | |
| SCHEMBL12113006 | 0.83 | MAPT (0.71) | MEN1KMT2AMAPTTNKSPARP1 | |
| SCHEMBL6524056 | 0.81 | MAPT (0.69) | MEN1KMT2AMAPTTNKSPARP1 | |
| SCHEMBL3072969 | 0.80 | MEN1 (0.67) | MEN1KMT2AMAPTGABRPGABRD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6362341-B1 | ANTIINFLAMMATORY AGENTS | ATHENA NEUROSCIENCES, INC. | 2002-03-26 | — | — | US | claimed |
| EP-4701391-A2 | HETEROLEPTIC IRIDIUM COMPLEX | Universal Display Corporation (US) | 2026-02-25 | — | — | EP | disclosed |
| US-12550604-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| EP-3643721-B1 | HETEROLEPTIC IRIDIUM COMPLEX | UNIVERSAL DISPLAY CORP (US) | 2026-01-28 | — | — | EP | disclosed |
| US-20250268926-A1 | METHOD AND COMPOSITION FOR TREATING, ALLEVIATING OR PREVENTING A DISEASE OR CONDITION CAUSED BY AIR POLLUTANT | HONG KONG BAPTIST UNIVERSITY (CN) | 2025-08-28 | — | — | US | disclosed |
| US-20240180020-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2024-05-30 | — | — | US | disclosed |
| US-20240092744-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | THE NATIONAL INSTITUTES OF PHARMACEUTICAL R&D CO., LTD (CN) | 2024-03-21 | — | — | US | disclosed |
| US-11910701-B2 | Organic electroluminescent materials and devices | UNIVERSAL DISPLAY CORPORATION (US) | 2024-02-20 | — | — | US | disclosed |
| EP-4273150-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd (CN) | 2023-11-08 | — | — | EP | disclosed |
| US-20230309376-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | UNIVERSAL DISPLAY CORPORATION (US) | 2023-09-28 | — | — | US | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| EP-1379239-A2 | N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2004-01-14 | — | — | EP | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| WO-2002078693-A2 | N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR | ELI LILLY AND COMPANY (US) | 2002-10-10 | — | — | WO | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| US-6432955-B1 | ANTICOAGULANTS | AKZO NOBEL N.V. (NL) | 2002-08-13 | — | — | US | disclosed |
| US-6194409-B1 | SERINE PROTEASE INHIBITOR; BIOAVAILABILITY WHEN ADMINISTERED BY MOUTH | AKZO NOBEL N.V. (NL) | 2001-02-27 | — | — | US | disclosed |
| US-6037361-A | GELATINASE, STROMELYSIN, COLLAGENASE, AND MATRILYSIN INHIBITORS; MULTIPLE SCLEROSIS TREATMENT; BRAIN AND NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY (US) | 2000-03-14 | — | — | US | disclosed |
| EP-0975600-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | Akzo Nobel N.V. (NL) | 2000-02-02 | — | — | EP | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11910701-B2 | Organic electroluminescent materials and devices | ICOSLG, PDCD1LG2, NECTIN4 | MEN1 2086/4885KMT2A 2568/4885MAPT 910/4885 |
| US-20240180020-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | ICOSLG, PDCD1LG2, NECTIN4 | MEN1 2086/4885KMT2A 2568/4885MAPT 910/4885 |
| US-20240092744-A1 | TRICYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | GOT2, HADH, CYP4A11 | MEN1 955/4885KMT2A 3581/4885MAPT 2211/4885 |
| US-20230309376-A1 | ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES | ICOSLG, PDCD1LG2, NECTIN4 | MEN1 2086/4885KMT2A 2568/4885MAPT 910/4885 |
| US-12550604-B2 | Organic electroluminescent materials and devices | ROS1, DNMT3A, PRDM9 | MEN1 1230/4885KMT2A 880/4885MAPT 1607/4885 |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | MEN1 1002/4885KMT2A 2507/4885MAPT 4873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.